GKV Capital Management Co. Inc. Makes New $11.94 Million Investment in Eli Lilly and Company (NYSE:LLY)

GKV Capital Management Co. Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 15,462 shares of the company's stock, valued at approximately $11,937,000. Eli Lilly and Company accounts for approximately 4.9% of GKV Capital Management Co. Inc.'s portfolio, making the stock its 4th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Commonwealth Financial Corp PA grew its stake in shares of Eli Lilly and Company by 1.8% in the 4th quarter. First Commonwealth Financial Corp PA now owns 2,093 shares of the company's stock worth $1,616,000 after purchasing an additional 37 shares during the last quarter. Capital Square LLC increased its holdings in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Capital Square LLC now owns 5,074 shares of the company's stock valued at $3,986,000 after buying an additional 14 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $14,828,000. Farringdon Capital Ltd. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth $954,000. Finally, Demars Financial Group LLC raised its position in shares of Eli Lilly and Company by 77,111.9% during the fourth quarter. Demars Financial Group LLC now owns 518,864 shares of the company's stock worth $400,563,000 after purchasing an additional 518,192 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LLY shares. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Guggenheim decreased their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,012.00.

Eli Lilly and Company Price Performance

NYSE LLY traded up $106.80 on Friday, hitting $841.70. 10,843,294 shares of the company were exchanged, compared to its average volume of 3,427,703. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a market cap of $798.08 billion, a P/E ratio of 71.88, a P/E/G ratio of 1.40 and a beta of 0.51. The firm has a 50 day moving average of $829.09 and a two-hundred day moving average of $820.35. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.